# NCT03425643 (NCT03425643)

> Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03425643
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab; Placebo; Cisplatin; Gemcitabine; Pemetrexed
- Enrollment: 797
- Primary outcome: Event Free Survival (EFS)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 14

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03425643

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03425643", "email": "<work email>"}; the inbox owner confirms by the emailed link.